Clinical Trial: A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma

U.S., Sept. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07799220) titled 'A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma' on Aug. 26.

Brief Summary: The researchers are doing this study to find out whether the combination of zanubrutinib, obinutuzumab, and sonrotoclax (BOSon) is an effective treatment approach for people with mantle cell lymphoma (MCL).

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: Mantle Cell Lymphoma

Intervention: DRUG: Zanubrutinib

PO twice daily of each 28-day cycle

DRUG: Obinutuzumab

IVPB on days 1, 8, and 15 of cycle 1; and IVPB on day 1 of cycles 2-8

DRUG: Sonrotoclax

Sonrotoclax will be initiated on C2D1 ...